40 completed, 6 active not recruiting, 6 recruiting, 5 unknown. 18 Phase 2, 13 Not applicable, 12 Phase 3, 7 Phase 1, 2 Early Phase 1.
Follow Myositis, Inclusion Body: new trials by email Literature Review of Myositis, Inclusion Body trials Research Report on Myositis, Inclusion Body
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis IBM, Inclusion Body Myositis | Recruiting | Johns Hopkins University | 30 | 2026-10-01 | 2026-09-16 | |
| The Aim of the Study is to Characterize Patients Exhibiting Muscular Atrophy and Weakness Who Require a Muscle Biopsy for Diagnosis (IBM vs Atypical MND), Through an Innovative Technique Which Enables the Evaluation of the Neuromuscular Junction Involvement in Each Condition Inclusion Body Myositis (IBM), Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Active not recruiting | IRCCS San Raffaele | 30 | 2026-07-01 | 2026-09-01 | |
| IBM Dietary Surveillance Study Whole-Body Dual-Energy X-ray Absorptiometry, Anthropometry, Capillary Blood Sampling - Inclusion Body Myositis | Not yet recruiting | Manchester Metropolitan University | 47 | 2026-04-30 | 2026-04-17 | |
| Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease Whole-body Electrical Muscle Stimulation Exercise - Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis | Not applicable | Recruiting | University of Missouri-Columbia | 50 | 2026-03-10 | 2026-03-17 |
| The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period. Assistive gait devices combined with physiotherapy - Inclusion Body Myositis, Myotonic Dystrophy 1 | Not applicable | Enrolling by invitation | LMU Klinikum | 30 | 2025-09-01 | 2025-07-18 |
| MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS) No intervention - qualitative and mixed methods investigations - IBM, IIM | Recruiting | Myositis International Health & Research Collaborative Alliance Foundation | 700 | 2025-06-25 | 2026-01-28 | |
| Ruxolitinib Treatment in Inclusion Body Myositis Ruxolitinib, Placebo - Inclusion Body Myositis, Sporadic | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 80 | 2025-05-27 | 2026-05-29 |
| Exercise as Treatment for Patients With Inclusion Body Myositis Exercise group in a hospital setting - Inclusion Body Myositis (IBM), Feasibility Study | Not applicable | Completed | Oslo University Hospital | 15 | 2025-01-06 | 2025-06-24 |
| Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis Ulviprubart (ABC008) - Inclusion Body Myositis (IBM) | Phase 2 / Phase 3 | Active not recruiting | Abcuro, Inc. | 270 | 2024-10-21 | 2025-07-28 |
| Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders FBIndex - Inclusion Body Myositis, Myotonic Dystrophy | Enrolling by invitation | LMU Klinikum | 108 | 2024-09-09 | 2025-09-10 | |
| Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis Pozelimab/Cemdisiran - Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies | Early Phase 1 | Recruiting | Austin Neuromuscular Center | 10 | 2024-08-08 | 2026-01-16 |
| Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time PAMSys pendant PAMSys wrist sensors - Inclusion Body Myositis | Active not recruiting | University of Kansas Medical Center | 20 | 2023-11-16 | 2026-06-29 | |
| The Risk of Falls Index for Patients With Neuromuscular Disorders The risk of falls - Inclusion Body Myositis, Myotonic Dystrophy | Completed | LMU Klinikum | 30 | 2023-09-01 | 2024-09-19 | |
| Effect of 8-week Supplementation With Black Chokeberry on Recovery in Highly Trained Rowers black chokeberry (Aronia melanocarpa), Placebo - Inflammation;Muscle(S), Oxidative Stress Injury | Phase 4 | Completed | Poznan University of Physical Education | 15 | 2023-04-01 | 2024-04-26 |
| A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis ABC008 - Inclusion Body Myositis | Phase 2 / Phase 3 | Completed | Abcuro, Inc. | 272 | 2023-02-28 | 2026-10-01 |
| Cell Therapy for IBM by Muscle Injection of ADSVF ADSVF - Inclusion Body Myositis | Phase 1 | Unknown | Assistance Publique - Hôpitaux de Paris | 32 | 2023-02-01 | 2023-03-22 |
| Phase III Trial of Sirolimus in IBM Sirolimus, Placebo - Inclusion Body Myositis | Phase 3 | Active not recruiting | University of Kansas Medical Center | 140 | 2022-07-01 | 2026-01-14 |
| Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease Beck depression inventory fast screen (Questionnaire), Brief Pain Inventory (BPI) (Questionnaire), German Pain Inventory (Questionnaire) - Pompe Disease (Late-onset), Inclusion Body Myositis | Unknown | LMU Klinikum | 95 | 2022-03-31 | 2023-10-10 | |
| Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells Adipose Derived Regenerative Cells - Inclusion Body Myositis | Not applicable | Completed | University of Kansas Medical Center | 9 | 2022-03-10 | 2025-12-17 |
Showing 20 of 65. Sign in to see all of them.
Myositis (18) · Polymyositis (11) · Dermatomyositis (10) · Glycogen Storage Disease Type II (5) · Muscular Dystrophy, Facioscapulohumeral (5) · Neuromuscular Diseases (5) · Amyotrophic Lateral Sclerosis (4) · Myotonic Dystrophy (4) · Lambert-Eaton Myasthenic Syndrome (3) · Muscular Atrophy, Spinal (3) · Muscular Diseases (3) · Myasthenia Gravis (3) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (3) · Asthenia (2)
Musculoskeletal Diseases (64) · Nervous System Diseases (63) · Muscular Diseases (62) · Neuromuscular Diseases (60) · Myositis (47) · Pathological Conditions, Signs and Symptoms (14) · Skin Diseases (11) · Skin and Connective Tissue Diseases (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Connective Tissue Diseases (9) · Nutritional and Metabolic Diseases (9) · Pathologic Processes (9) · Metabolic Diseases (8) · Muscular Disorders, Atrophic (8)
bimagrumab (4) · Blood Specimen Collection (3) · arimoclomol (3) · Sirolimus (2) · Vital Signs (2) · Walk Test (2) · siponimod (2) · Acceptance and Commitment Therapy (1) · Alemtuzumab (1) · Anthropometry (1) · Calorimetry, Indirect (1) · Cholecalciferol (1) · Etanercept (1) · Flavonoids (1) · Infliximab (1)
Novartis Pharmaceuticals (6) · LMU Klinikum (5) · University of Kansas Medical Center (4) · Abcuro, Inc. (3) · Assistance Publique - Hôpitaux de Paris (3) · National Institute of Neurological Disorders and Stroke (NINDS) (3) · Johns Hopkins University (2) · Karolinska Institutet (2) · National Institute of Environmental Health Sciences (NIEHS) (2) · Phoenix Neurological Associates, LTD (2) · ZevraDenmark (2) · Austin Neuromuscular Center (1) · Catherine Buettner (1) · Centre Hospitalier Universitaire de Nice (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1)
United States (37) · United Kingdom (10) · France (9) · Germany (7) · Australia (6) · Italy (4) · Belgium (3) · Denmark (3) · Netherlands (3) · Canada (2) · Czechia (2) · Hungary (2) · Japan (2) · Poland (2) · Sweden (2)
Mazen Dimachkie (2) · Mazen Dimachkie, MD (2) · Stephan Wenninger, PD Dr. med. (2) · Abdullah Z AlQahtani, MD MPH (1) · Adam I Schiffenbauer, M.D. (1) · Aleksandar Radunovic (1) · Andrew L Mammen, M.D. (1) · Bhaskar Roy, MBBS (1) · Catherine Buettner, MD, MPH (1) · Christopher C Cheatham, Ph.D. (1) · Christopher Graham (1)
PMID 12610846, PMID 16267188, PMID 16849828, PMID 16900450, PMID 19454532, PMID 19927034, PMID 22003934, PMID 25201017, PMID 25201624, PMID 25322757, PMID 25381300, PMID 28168524, PMID 30287669, PMID 31396142, PMID 31397289, PMID 32690797, PMID 33597289, PMID 35192788, PMID 35595645, PMID 37739573, PMID 38059274, PMID 38273639, PMID 38960586, PMID 40018746, PMID 40152935, PMID 40873756, PMID 41832158, PMID 9324080
2008 (1), 2015 (1), 2018 (1), K23AR055664 (1), R01AR078340 (1)